검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | oncolytic vaccinia virus (IDOV-Immune, IDOV-Immune (oncolytic vaccinia virus)) ViroMissile, Inc.·Colorectal Cancer ORR 80% |
|---|---|
Overview Program | IDOV-Immune (oncolytic vaccinia virus) |
Overview Company | ViroMissile, Inc. |
Overview Modality | CGT |
Overview Target | Colorectal Cancer |
Overview Indication | Colorectal Cancer; Pancreatic Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway |
MoA Biomarker | PD-1-directed IL-2 expression |
PK/PD Species | Dog |
PK/PD Animal (cat.) | Dog, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Dog |
Toxicology Animal (cat.) | Dog, In vitro |
Toxicology Major finding | Oncolytic Viruses for Cancer Therapy in Dogs.. Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. T… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical PFS | 10 |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT02759588 |
Clinical Data Tier / Score | A · 66 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | oncolytic vaccinia virus (IDOV-Immune, IDOV-Immune (oncolytic vaccinia virus)) ViroMissile, Inc.·Colorectal Cancer ORR 80% |
|---|---|
Overview Program | IDOV-Immune (oncolytic vaccinia virus) |
Overview Company | ViroMissile, Inc. |
Overview Modality | CGT |
Overview Target | Colorectal Cancer |
Overview Indication | Colorectal Cancer; Pancreatic Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway |
MoA Biomarker | PD-1-directed IL-2 expression |
PK/PD Species | Dog |
PK/PD Animal (cat.) | Dog, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Dog |
Toxicology Animal (cat.) | Dog, In vitro |
Toxicology Major finding | Oncolytic Viruses for Cancer Therapy in Dogs.. Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. T… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical PFS | 10 |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT02759588 |
Clinical Data Tier / Score | A · 66 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교